Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025Cyprium is eligible to receive royalties and up to $129 ...
AI detects ovarian cancer better than human experts in new study
Join Fox News for access to this content Plus special access to select articles and other premium content with your account - ...
News Medical on MSN31m
NUS researchers enhance chemotherapy with magnetic field pulses
Researchers at the National University of Singapore (NUS) have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects.